NCT04630522View on ClinicalTrials.gov

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

295

Participants

Timeline

Start Date

October 31, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Bone Metastases From Solid Tumors
Interventions
DRUG

Drug: JMT103- 120 mg SC Q4W

JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.

DRUG

Drug: JMT103- 120 mg SC Q8W

JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.

DRUG

Drug: JMT103- 180 mg SC Q8W

JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.

DIETARY_SUPPLEMENT

Dietary Supplement: Calcium Dietary Supplement: Vitamin D

Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.

Trial Locations (1)

200123

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY

NCT04630522 - Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors | Biotech Hunter | Biotech Hunter